Titre : Motifs et domaines d'intéraction protéique

Motifs et domaines d'intéraction protéique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Motifs et domaines d'intéraction protéique : Questions médicales les plus fréquentes", "headline": "Motifs et domaines d'intéraction protéique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Motifs et domaines d'intéraction protéique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Motifs et domaines d'intéraction protéique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éléments structuraux des protéines", "url": "https://questionsmedicales.fr/mesh/D000072416", "about": { "@type": "MedicalCondition", "name": "Éléments structuraux des protéines", "code": { "@type": "MedicalCode", "code": "D000072416", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Domaine B30.2-SPRY", "alternateName": "B30.2-SPRY Domain", "url": "https://questionsmedicales.fr/mesh/D000071197", "about": { "@type": "MedicalCondition", "name": "Domaine B30.2-SPRY", "code": { "@type": "MedicalCode", "code": "D000071197", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.290" } } }, { "@type": "MedicalWebPage", "name": "Domaine BTB-POZ", "alternateName": "BTB-POZ Domain", "url": "https://questionsmedicales.fr/mesh/D000071757", "about": { "@type": "MedicalCondition", "name": "Domaine BTB-POZ", "code": { "@type": "MedicalCode", "code": "D000071757", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.343" } } }, { "@type": "MedicalWebPage", "name": "Superfamille des domaines de mort", "alternateName": "Death Domain Superfamily", "url": "https://questionsmedicales.fr/mesh/D000071458", "about": { "@type": "MedicalCondition", "name": "Superfamille des domaines de mort", "code": { "@type": "MedicalCode", "code": "D000071458", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Domaine d'activation et de recrutement des caspases", "alternateName": "Caspase Activation and Recruitment Domain", "url": "https://questionsmedicales.fr/mesh/D000071476", "about": { "@type": "MedicalCondition", "name": "Domaine d'activation et de recrutement des caspases", "code": { "@type": "MedicalCode", "code": "D000071476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.250" } } }, { "@type": "MedicalWebPage", "name": "Domaine de mort", "alternateName": "Death Domain", "url": "https://questionsmedicales.fr/mesh/D000071459", "about": { "@type": "MedicalCondition", "name": "Domaine de mort", "code": { "@type": "MedicalCode", "code": "D000071459", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.500" } } }, { "@type": "MedicalWebPage", "name": "Domaine effecteur de mort", "alternateName": "Death Effector Domain", "url": "https://questionsmedicales.fr/mesh/D000071461", "about": { "@type": "MedicalCondition", "name": "Domaine effecteur de mort", "code": { "@type": "MedicalCode", "code": "D000071461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.750" } } }, { "@type": "MedicalWebPage", "name": "Domaine pyrine", "alternateName": "Pyrin Domain", "url": "https://questionsmedicales.fr/mesh/D000071196", "about": { "@type": "MedicalCondition", "name": "Domaine pyrine", "code": { "@type": "MedicalCode", "code": "D000071196", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Domaines FERM", "alternateName": "FERM Domains", "url": "https://questionsmedicales.fr/mesh/D000075926", "about": { "@type": "MedicalCondition", "name": "Domaines FERM", "code": { "@type": "MedicalCode", "code": "D000075926", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.422" } } }, { "@type": "MedicalWebPage", "name": "Domaines MYND", "alternateName": "MYND Domains", "url": "https://questionsmedicales.fr/mesh/D000074608", "about": { "@type": "MedicalCondition", "name": "Domaines MYND", "code": { "@type": "MedicalCode", "code": "D000074608", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.474" } } }, { "@type": "MedicalWebPage", "name": "Domaines PDZ", "alternateName": "PDZ Domains", "url": "https://questionsmedicales.fr/mesh/D054731", "about": { "@type": "MedicalCondition", "name": "Domaines PDZ", "code": { "@type": "MedicalCode", "code": "D054731", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.500" } } }, { "@type": "MedicalWebPage", "name": "Domaines à doigts de zinc de type RING", "alternateName": "RING Finger Domains", "url": "https://questionsmedicales.fr/mesh/D054829", "about": { "@type": "MedicalCondition", "name": "Domaines à doigts de zinc de type RING", "code": { "@type": "MedicalCode", "code": "D054829", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.625" } } }, { "@type": "MedicalWebPage", "name": "Domaine d'homologie SRC", "alternateName": "src Homology Domains", "url": "https://questionsmedicales.fr/mesh/D018909", "about": { "@type": "MedicalCondition", "name": "Domaine d'homologie SRC", "code": { "@type": "MedicalCode", "code": "D018909", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.750" } } }, { "@type": "MedicalWebPage", "name": "Motif stérile alpha", "alternateName": "Sterile Alpha Motif", "url": "https://questionsmedicales.fr/mesh/D000071682", "about": { "@type": "MedicalCondition", "name": "Motif stérile alpha", "code": { "@type": "MedicalCode", "code": "D000071682", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.813" } } }, { "@type": "MedicalWebPage", "name": "Domaine Tudor", "alternateName": "Tudor Domain", "url": "https://questionsmedicales.fr/mesh/D000071856", "about": { "@type": "MedicalCondition", "name": "Domaine Tudor", "code": { "@type": "MedicalCode", "code": "D000071856", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.844" } } }, { "@type": "MedicalWebPage", "name": "Domaines WW", "alternateName": "WW Domains", "url": "https://questionsmedicales.fr/mesh/D000074585", "about": { "@type": "MedicalCondition", "name": "Domaines WW", "code": { "@type": "MedicalCode", "code": "D000074585", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.937" } } } ], "about": { "@type": "MedicalCondition", "name": "Motifs et domaines d'intéraction protéique", "alternateName": "Protein Interaction Domains and Motifs", "code": { "@type": "MedicalCode", "code": "D054730", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ylva Ivarsson", "url": "https://questionsmedicales.fr/author/Ylva%20Ivarsson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry-BMC, Uppsala University, Box 576, SE-751 23 Uppsala, Sweden. Electronic address: Yiva.ivarson@kemi.uu.se." } }, { "@type": "Person", "name": "Sobia Idrees", "url": "https://questionsmedicales.fr/author/Sobia%20Idrees", "affiliation": { "@type": "Organization", "name": "School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia." } }, { "@type": "Person", "name": "Keshav Raj Paudel", "url": "https://questionsmedicales.fr/author/Keshav%20Raj%20Paudel", "affiliation": { "@type": "Organization", "name": "Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology Sydney, Australia." } }, { "@type": "Person", "name": "Per Jemth", "url": "https://questionsmedicales.fr/author/Per%20Jemth", "affiliation": { "@type": "Organization", "name": "Department of Medical Biochemistry and Microbiology, Uppsala University, BMC Box 582, SE-75123 Uppsala, Sweden. Electronic address: Per.Jemth@imbim.uu.se." } }, { "@type": "Person", "name": "Norman E Davey", "url": "https://questionsmedicales.fr/author/Norman%20E%20Davey", "affiliation": { "@type": "Organization", "name": "Division of Cancer Biology, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Setting 6-Minute Minimal Examination Time Improves the Detection of Focal Upper Gastrointestinal Tract Lesions During Endoscopy: A Multicenter Prospective Study.", "datePublished": "2023-08-01", "url": "https://questionsmedicales.fr/article/37307142", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14309/ctg.0000000000000612" } }, { "@type": "ScholarlyArticle", "name": "A multicenter real-world study comparing the clinical equivalence of trastuzumab biosimilar HLX02 and reference trastuzumab in the treatment of HER-2-positive breast cancer.", "datePublished": "2023-07-15", "url": "https://questionsmedicales.fr/article/37559995", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } }, { "@type": "ScholarlyArticle", "name": "Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study.", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37453486", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijid.2023.07.004" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37421604", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ajh.26998" } }, { "@type": "ScholarlyArticle", "name": "Incidence of and risk factors for postoperative ileus between right and left laparoscopic colectomy using propensity-score-matched analysis: A retrospective multicenter study.", "datePublished": "2023-07-06", "url": "https://questionsmedicales.fr/article/37409677", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ases.13227" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes chimiques", "item": "https://questionsmedicales.fr/mesh/D055598" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes biochimiques", "item": "https://questionsmedicales.fr/mesh/D001669" }, { "@type": "ListItem", "position": 4, "name": "Conformation moléculaire", "item": "https://questionsmedicales.fr/mesh/D008968" }, { "@type": "ListItem", "position": 5, "name": "Conformation des protéines", "item": "https://questionsmedicales.fr/mesh/D011487" }, { "@type": "ListItem", "position": 6, "name": "Éléments structuraux des protéines", "item": "https://questionsmedicales.fr/mesh/D000072416" }, { "@type": "ListItem", "position": 7, "name": "Motifs et domaines d'intéraction protéique", "item": "https://questionsmedicales.fr/mesh/D054730" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Motifs et domaines d'intéraction protéique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Motifs et domaines d'intéraction protéique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Motifs et domaines d'intéraction protéique", "description": "Comment identifier un domaine d'interaction protéique ?\nQuels tests sont utilisés pour analyser les interactions protéiques ?\nLes motifs d'interaction peuvent-ils être prédits ?\nQuels marqueurs indiquent une interaction protéique ?\nComment les mutations affectent-elles les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Motifs et domaines d'intéraction protéique", "description": "Quels symptômes indiquent une dysfonction protéique ?\nLes interactions protéiques peuvent-elles causer des maladies ?\nComment les maladies génétiques affectent-elles les interactions ?\nQuels signes cliniques sont liés aux troubles d'interaction ?\nLes infections peuvent-elles perturber les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Motifs et domaines d'intéraction protéique", "description": "Comment prévenir les maladies liées aux interactions protéiques ?\nLes dépistages sont-ils utiles pour les troubles protéiques ?\nL'éducation sur les interactions protéiques est-elle importante ?\nLes vaccins influencent-ils les interactions protéiques ?\nComment le stress affecte-t-il les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Motifs et domaines d'intéraction protéique", "description": "Quels traitements ciblent les interactions protéiques ?\nComment la thérapie génique influence-t-elle les interactions ?\nLes inhibiteurs de protéines sont-ils efficaces ?\nComment les traitements ciblent-ils les motifs d'interaction ?\nLes thérapies combinées sont-elles bénéfiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Motifs et domaines d'intéraction protéique", "description": "Quelles complications peuvent survenir avec des interactions anormales ?\nLes complications sont-elles réversibles ?\nComment les interactions affectent-elles le vieillissement ?\nLes maladies auto-immunes sont-elles liées aux interactions ?\nLes troubles métaboliques sont-ils causés par des interactions ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Motifs et domaines d'intéraction protéique", "description": "Quels facteurs augmentent le risque de troubles protéiques ?\nLe vieillissement est-il un facteur de risque ?\nLes infections virales influencent-elles les interactions ?\nLe mode de vie peut-il affecter les interactions protéiques ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un domaine d'interaction protéique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des méthodes bioinformatiques et des expériences de biologie moléculaire." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les interactions protéiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent le co-immunoprécipitation et les essais de double hybride." } }, { "@type": "Question", "name": "Les motifs d'interaction peuvent-ils être prédits ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des outils bioinformatiques permettent de prédire les motifs d'interaction dans les protéines." } }, { "@type": "Question", "name": "Quels marqueurs indiquent une interaction protéique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des changements de conformation ou des complexes protéiques stables peuvent indiquer une interaction." } }, { "@type": "Question", "name": "Comment les mutations affectent-elles les interactions protéiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les mutations peuvent altérer la structure des motifs, perturbant ainsi les interactions normales." } }, { "@type": "Question", "name": "Quels symptômes indiquent une dysfonction protéique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés comme la fatigue, des troubles métaboliques ou des maladies auto-immunes." } }, { "@type": "Question", "name": "Les interactions protéiques peuvent-elles causer des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions anormales peuvent contribuer à des maladies comme le cancer ou Alzheimer." } }, { "@type": "Question", "name": "Comment les maladies génétiques affectent-elles les interactions ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des défauts dans les motifs d'interaction, perturbant les fonctions cellulaires." } }, { "@type": "Question", "name": "Quels signes cliniques sont liés aux troubles d'interaction ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'inflammation, la douleur ou des anomalies neurologiques peuvent apparaître." } }, { "@type": "Question", "name": "Les infections peuvent-elles perturber les interactions protéiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains pathogènes modifient les interactions protéiques pour favoriser leur survie." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux interactions protéiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques." } }, { "@type": "Question", "name": "Les dépistages sont-ils utiles pour les troubles protéiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages précoces peuvent aider à identifier des risques de maladies génétiques." } }, { "@type": "Question", "name": "L'éducation sur les interactions protéiques est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre les interactions peut aider à prévenir des maladies et à promouvoir la santé." } }, { "@type": "Question", "name": "Les vaccins influencent-ils les interactions protéiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins peuvent moduler les interactions immunitaires, renforçant la réponse du corps." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il les interactions protéiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut altérer les interactions protéiques, affectant la santé globale et le bien-être." } }, { "@type": "Question", "name": "Quels traitements ciblent les interactions protéiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de protéines ou des anticorps monoclonaux sont utilisés." } }, { "@type": "Question", "name": "Comment la thérapie génique influence-t-elle les interactions ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut corriger des mutations, rétablissant ainsi des interactions protéiques normales." } }, { "@type": "Question", "name": "Les inhibiteurs de protéines sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent bloquer des interactions spécifiques, offrant des options thérapeutiques." } }, { "@type": "Question", "name": "Comment les traitements ciblent-ils les motifs d'interaction ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils visent à modifier ou à bloquer des motifs spécifiques pour restaurer la fonction cellulaire." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles bénéfiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent cibler plusieurs interactions protéiques, améliorant l'efficacité du traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des interactions anormales ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des cancers, des maladies neurodégénératives ou des troubles métaboliques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Comment les interactions affectent-elles le vieillissement ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des interactions protéiques altérées peuvent accélérer le vieillissement cellulaire et tissulaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles liées aux interactions ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions anormales peuvent déclencher des réponses auto-immunes dans l'organisme." } }, { "@type": "Question", "name": "Les troubles métaboliques sont-ils causés par des interactions ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions protéiques défectueuses peuvent entraîner des déséquilibres métaboliques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de troubles protéiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme la génétique, l'environnement et le mode de vie influencent le risque." } }, { "@type": "Question", "name": "Le vieillissement est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la stabilité et la fonction des interactions protéiques." } }, { "@type": "Question", "name": "Les infections virales influencent-elles les interactions ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber les interactions protéiques, augmentant les risques." } }, { "@type": "Question", "name": "Le mode de vie peut-il affecter les interactions protéiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée et le manque d'exercice peuvent altérer les interactions." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des toxines ou des polluants peuvent affecter les interactions protéiques et la santé." } } ] } ] }

Sous-catégories

15 au total

Sources (10000 au total)

Setting 6-Minute Minimal Examination Time Improves the Detection of Focal Upper Gastrointestinal Tract Lesions During Endoscopy: A Multicenter Prospective Study.

Positive correlation between examination time and neoplasm detection using esophagogastroduodenoscopy (EGD) has been described by observational studies, but the effect of setting minimal examination t... This prospective, 2-stage, interventional study was conducted in 7 tertiary hospitals in China, enrolling consecutive patients undergoing intravenously sedated diagnostic EGDs. In stage I, the baselin... A total of 847 and 1,079 EGDs performed by 21 endoscopists were included in stages I and II, respectively. In stage II, the minimal examination time was set as 6 minutes, and the median time for norma... Setting a 6-minute minimal examination time significantly improved the detection of focal lesions during EGDs and has the potential to be implemented for quality improvement....

Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study.

AmpC β-lactamase-hyperproducing Enterobacterales (ABLHE) bloodstream infections (BSI) are emerging and leading to therapeutic challenges worldwide. Prescriptions of carbapenems may lead to the emergen... This retrospective multicenter study included patients with ABLHE BSI from two tertiary hospitals in France, between July 2017 and July 2022. Non-AmpC-producing Enterobacterales, extended-spectrum β-l... We analyzed 164 BSI, which included 77 in the cefepime group and 87 in the carbapenem group. In the weighted cohort, the 30-day mortality rates were similar between the cefepime group (23.3%) and the ... This study adds evidence in favor of the use of cefepime for treating third-generation cephalosporin-resistant ABLHE BSI in case of minimal inhibitory concentration ≤ 1 mg/l, which could spare carbape...

Incidence of and risk factors for postoperative ileus between right and left laparoscopic colectomy using propensity-score-matched analysis: A retrospective multicenter study.

In colon cancer, the incidence of postoperative ileus is reportedly higher for the right-side than for the left-side colon, but those studies included small numbers of subjects and contained several b... This multicenter study reviewed 1986 patients who underwent laparoscopic colectomy between 2016 and 2021 for right-side (n = 907) and left-side (n = 1079) colon cancer. After propensity score matching... Postoperative ileus occurred in 97 patients. Before matching, the proportion of female patients and median age were higher and frequency of preoperative stent insertion was lower with right colectomy ... This study revealed a higher risk of postoperative ileus after right colectomy with laparoscopic surgery. Male gender and history of abdominal surgery were risk factors for postoperative ileus after r...

Evaluation of the one-step nucleic acid amplification method for rapid detection of lymph node metastases in endometrial cancer: prospective, multicenter, comparative study.

To evaluate the diagnostic performance of the one-step nucleic acid amplification (OSNA) method for the detection of sentinel lymph node (SLN) metastases in women with apparent early-stage endometrial... Prospective, multicentric, interventional study. Patients with apparent early-stage endometrial cancer who underwent primary surgical staging with SLN mapping were included. SLNs were serially section... Three-hundred and sixteen patients with 668 SLNs were included. OSNA assay detected 22 (3.3%) positive SLNs, of which 17 (2.5%) were micrometastases and 5 (0.7%) macrometastases, whereas ultrastaging ... The OSNA method had high specificity and high accuracy in detecting SLN metastasis in apparent early-stage endometrial cancer. The advantage of the OSNA method could be represented as the possibility ...

Role of Endoscopic Biopsies and Morphologic Features in Predicting Microsatellite Instability Status in Gastric Cancer: A Multicenter Comparative Study of Endoscopic Biopsies and Surgical Specimens.

Evaluation of mismatch repair (MMR) protein and microsatellite instability (MSI) status plays a pivotal role in the management of gastric cancer (GC) patients. In this study, we aimed to evaluate the ...

Acute Disorders of Consciousness in Pediatric Severe Sepsis and Organ Failure: Secondary Analysis of the Multicenter Phenotyping Sepsis-Induced Multiple Organ Failure Study.

Acute disorders of consciousness (DoC) in pediatric severe sepsis are associated with increased risk of morbidity and mortality. We sought to examine the frequency of and factors associated with DoC i... Secondary analysis of the multicenter Phenotyping Sepsis-Induced Multiple Organ Failure Study (PHENOMS).... Nine tertiary care PICUs in the United States.... Children less than 18 years old admitted to a PICU with severe sepsis and at least one organ failure during a PICU stay.... None.... The primary outcome was frequency of DoC, defined as Glasgow Coma Scale (GCS) less than 12 in the absence of sedatives during an ICU stay, among children with severe sepsis and the following: single o... One of every five children with severe sepsis and organ failure experienced acute DoC during their PICU stay. Preliminary findings suggest the need for prospective evaluation of DoC in children with s...

Management of small subepithelial tumors by endoscopic banding without resection and single-incision needle-knife-assisted biopsy sampling: a prospective multicenter study.

Endoscopic band ligation (EBL) without resection combined with single-incision needle-knife (SINK) biopsy sampling may have a positive impact on small GI subepithelial tumor (SET) management, but the ... This prospective multicenter observational cohort study in 7 centers included patients with SETs ≤15 mm (confirmed by EUS) between March 2017 and March 2020. The primary outcome was clinical success a... Of 273 patients screened, 122 (62.3% women; mean age, 60.9 ± 13.2 years) were included with SETs (mean size, 9 ± 2.8 mm; gastric location, 77%; superficial layer dependence, 63%). The primary endpoint... EBL plus SINK biopsy sampling seems to be feasible and safe, and it may offer a favorable clinical impact in small-sized SETs. In particular, SETs ≤10 mm are the best candidates. (Clinical trial regis...

Surgical site infection after intracorporeal and extracorporeal anastomosis in laparoscopic left colectomy for colon cancer: a multicenter propensity score-matched cohort study.

Intracorporeal anastomosis (IA) is associated with reduced surgical site infection (SSI) and other postoperative complications in laparoscopic right colectomy (LRC). However, evidence is inadequate fo... In this retrospective multicenter propensity score-matched (PSM) cohort study, we enrolled consecutive patients who underwent LLC with IA (TLLC/IA) and laparoscopic-assisted left colectomy with EA (LA... Overall, 574 and 99 patients received LALC/EA and TLLC/IA, respectively. After PSM, 84 patients with TLLC/IA were matched with 141 patients with LALC/EA. Thirty patients (13.3%) patients experienced S... IA in LLC is associated with a reduced risk of overall SSI and superficial/deep SSI. However, it may require a longer operating time....